trelstar and Epilepsy

Topics: Adolescent; Body Mass Index; Child; Epilepsy; Female; Follicle Stimulating Hormone; Follow-Up Studies; Gonadal Steroid Hormones; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Male; Obesity; Ovary; Puberty, Precocious; Testis; Triptorelin Pamoate

Prompted by findings of a hypoestrogenic state in girls during prolonged treatment with GnRH agonist and a close association of estradiol serum concentrations with uterine volume in puberty, this study sought to evaluate uterine and ovarian size in girls with precocious puberty (PP) during and after treatment and the effect of age or duration of treatment.. Patients with idiopathic central PP before (n = 75), during (n = 41) or after (n = 30) treatment with GnRH agonist underwent transabdominal pelvic ultrasound examination. Findings were compared with those in 69 girls with epilepsy and no PP before initiation of anticonvulsant treatment.. The girls with PP had significantly greater uterine and ovarian volumes before, during and after treatment with GnRH agonist than the controls, after adjusting for age at examination, weight, height and pubic and breast status. The average interval between the last treatment and the ultrasound examination was 1.3 years. There was no significant correlation between age at first treatment and uterine volume after treatment. Uterine volume decreased during treatment. There was a significant negative correlation between treatment duration and uterine volume after treatment (R(2) = -0.175, P = 0.024). Nevertheless, mean uterine volume was still greater in the treated group than in the control group (P = 0.002).. The iatrogenic hypoestrogenic state in treated girls with PP does not compromise post-pubertal uterine size.

Topics: Child; Epilepsy; Female; Gonadotropin-Releasing Hormone; Humans; Organ Size; Ovary; Pelvis; Puberty, Precocious; Triptorelin Pamoate; Ultrasonography; Uterus

Ten female patients suffering from catamenial epilepsy were treated with a synthetic analogue of the gonadotrophin releasing hormone (GnRH) in addition to antiepileptic drugs. Three of the patients became seizure free, in four patients seizure frequency decreased and in one patient seizures were of shorter duration. In only two of the patients was there no therapeutic effect. Adverse effects, including hot flushes, headache and increase in weight, were noticed in eight patients. These results support the hypothesis that treatment with a synthetic GnRH analogue might be helpful in patients with intractable catamenial epilepsies.

Topics: Adult; Anticonvulsants; Epilepsy; Estrogens; Female; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Menstrual Cycle; Middle Aged; Triptorelin Pamoate